ACTH prophylactic treatment of renal disorders
AssigneeQuestcor Pharmaceuticals, Inc.
InventorsSteve Cartt, Rujun Gong
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder.
Claims16
A method of prophylactically treating acute kidney injury (AKI) in an individual in need thereof comprising selecting an individual suspected of having, predisposed to, or at risk of developing acute kidney injury and administering an adrenocorticotropic hormone (ACTH) peptide to the individual in need thereof, wherein the ACTH peptide is administered as a first dose and one or more subsequent doses;
- and
- wherein the ACTH peptide is selected from the group consisting of:
- (a) the ACTH1-39 peptide consisting of the sequence:
- (SEQ ID NO:
- 1)
- H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
- 1 2 3 4 5 6 7 8 9 10
- Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-
- 11 12 13 14 15 16 17 18 19 20
- Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln-
- 21 22 23 24 25 26 27 28 29 30
- Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH;
- 31 32 33 34 35 36 37 38 39
- (b) the ACTH1-24 peptide consisting of the sequence:
- (SEQ ID NO:
- 2)
- H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
- 1 2 3 4 5 6 7 8 9 10
- Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-
- 11 12 13 14 15 16 17 18 19 20
- Lys-Val-Tyr-Pro;
- and
- 21 22 23 24
- (c) the ACTH peptide is ACTH1-17 peptide consisting of the sequence of:
- (SEQ ID NO:
- 3)
- H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
- 1 2 3 4 5 6 7 8 9 10
- Lys-Pro-Val-Gly-Lys-Lys-Arg.
- 11 12 13 14 15 16 17
A method of treating renal damage caused by ischemia to the kidney in an individual in need thereof comprising administering an adrenocorticotropic hormone (ACTH) peptide to the individual in need thereof, wherein the ACTH peptide is administered as a first dose and one or more subsequent doses;
- and
- wherein the ACTH peptide is selected from the group consisting of:
- (a) the ACTH1-39 peptide consisting of the sequence:
- (SEQ ID NO:
- 1)
- H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
- 1 2 3 4 5 6 7 8 9 10
- Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-
- 11 12 13 14 15 16 17 18 19 20
- Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln-
- 21 22 23 24 25 26 27 28 29 30
- Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH;
- 31 32 33 34 35 36 37 38 39
- (b) the ACTH1-24 peptide consisting of the sequence:
- (SEQ ID NO:
- 2)
- H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
- 1 2 3 4 5 6 7 8 9 10
- Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-
- 11 12 13 14 15 16 17 18 19 20
- Lys-Val-Tyr-Pro;
- and
- 21 22 23 24
- (c) the ACTH peptide is ACTH1-17 peptide consisting of the sequence:
- (SEQ ID NO:
- 3)
- H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
- 1 2 3 4 5 6 7 8 9 10
- Lys-Pro-Val-Gly-Lys-Lys-Arg.
- 11 12 13 14 15 16 17
Dependencies are inferred from the claim text.